Blog
RSS FeedPosted by Michael Wonder on 07 Nov 2023
NICE launches refreshed support service for life sciences industry
6 November 2023 - NICE has today launched its refreshed support service for the life sciences sector, NICE Advice. ...
Posted by Michael Wonder on 17 Feb 2023
High drug prices are not justified by industry’s spending on research and development
15 February 2023 - Aris Angelis and colleagues argue that by refocusing their spending drug companies could provide more innovative ...
Posted by Michael Wonder on 16 Dec 2021
Patient reported endpoints underrepresented in product information on new drugs
15 December 2021 - An IQWiG team analysed the extent to which patient reported outcomes, which were recorded as endpoints ...
Posted by Michael Wonder on 10 Jun 2021
Integrating early economic evaluation into target product profile development for medical tests: advantages and potential applications
7 June 2021 - Target product profiles outline the characteristics that new health care technologies require to address an unmet clinical ...
Posted by Michael Wonder on 16 Apr 2020
Biopharmaceutical sector waging war on COVID-19 with over 60 vaccines and medicines
16 April 2020 - The World Health Organization has declared that COVID-19 is a pandemic and 144 countries across the ...
Posted by Michael Wonder on 15 Apr 2020
COVID-19: NZ should develop vaccine programme, say scientists
15 April 2020 - New Zealand needs to act now to make sure it's not left behind when a successful ...
Posted by Michael Wonder on 12 Nov 2019
Labour peer says he opposes Corbyn-style state-funded drugs firm
12 November 2019 - A Labour peer has spoken out against the idea of a nationalised drugs industry, saying that ...
Posted by Michael Wonder on 09 Sep 2019
Subscription model for antibiotic development
6 September 2019 - An unlikely answer to the global crisis in antibiotic resistance. ...
Posted by Michael Wonder on 11 Jul 2019
New drugs: where did we go wrong and what can we do better?
10 July 2019 - More than half of new drugs entering the German health care system have not been shown to ...
Posted by Michael Wonder on 28 Mar 2019
Take over pharma to create new medicines, says top adviser
27 March 2019 - Part of the drugs industry should be taken over to make new antibiotics, an influential economist ...
Posted by Michael Wonder on 23 Feb 2019
Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model in a pharmaceutical company
21 February 2019 - Evidence requirements and assessment methods access differ between health technology assessment agencies. ...
Posted by Michael Wonder on 29 Jan 2019
NICE Scientific Advice launches collaborative programme with life sciences industry body
29 January 2019 - NICE has announced a collaboration with the body which represents life sciences organisations in the UK. ...
Posted by Michael Wonder on 16 Dec 2018
2019 oncology drugs in pipeline — survey
14 December 2018 - pCODR is again undertaking its periodic survey to facilitate consistent and systematic data collection from participating ...
Posted by Michael Wonder on 14 Jun 2018
Building synergy between regulatory and HTA agencies beyond processes and procedures—can we effectively align the evidentiary requirements? A survey of stakeholder perceptions
13 June 2018 - The pathway for bringing a new medicine to the market is dependent on two sequential processes: achieving ...
Posted by Michael Wonder on 05 Mar 2018
Guided by the research design: choosing the right statistical test
5 March 2018 - Choosing the right statistical test or model can be baffling for researchers, and if it is not ...